Cognitive behavior therapy for psychosis: A call to action

Clinical Psychology: Science and Practice

Volumn 12, Issue 1, 2005, Pages 68-71

  Mueser, Kim T ^a   Noordsy, Douglas L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cognitive behavior therapy; Polypharmacy; Psychiatry; Psychology; Psychosis; Schizophrenia; Severe mental illness

Indexed keywords

NEUROLEPTIC AGENT;

BEHAVIOR THERAPY; CLINICAL PSYCHOLOGY; COGNITIVE THERAPY; COMPETENCE; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL EDUCATION; MENTAL DISEASE; PRIMARY HEALTH CARE; PSYCHIATRY; PSYCHODYNAMICS; PSYCHOLOGIST; PSYCHOLOGY; PSYCHOSIS; PSYCHOTHERAPY; PUBLIC HEALTH SERVICE; REVIEW; SCHIZOPHRENIA; STANDARDIZATION; SYMPTOMATOLOGY; UNITED KINGDOM; UNITED STATES;

EID: 14644434392     PISSN: 09695893     EISSN: None     Source Type: Journal    
DOI: 10.1093/clipsy/bpi008     Document Type: Review

References (32)

1. Bond, G. R., Becker, D. R., Drake, R. E., Rapp, C. A., Meisler, N., Lehman, A. F., et al. (2001). Implementing supported employment as an evidence-based practice. Psychiatric Services, 52, 313 322.
2. Cather, C., Penn, D. L., Otto, M. W., Yovel, I., Mueser, K. T., & Goff, D. C. (in press). A pilot study of functional cognitive behavioral therapy (fCBT) for schizophrenia. Schizophrenia Research
3. Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. American Journal of Psychiatry, 161 700-706.
4. Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy. Schizophrenia Bulletin, 28, 75-84.
5. Covell, N. H., Jackson, C. T., Evans, A. C., & Essock, S. M. (2002). Antipsychotic prescribing practices in Connecticut's public mental health system: Rates of changing medications and prescribing styles. Schizophrenia Bulletin, 28, 17-29.
6. Dixon, L., McFarlane, W., Lefley, H., Lucksted, A., Cohen, C., Falloon, I., et al. (2001). Evidence-based practices for services to family members of people with psychiatric disabilities. Psychiatric Services, 52, 903-910.
7. Friedman, J., Ault, K., & Powchik, P. (1997). Pimozide augmentation for the treatment of schizophrenia patients who are partial responders to clozapine. Biological Psychiatry, 42, 522-523.
8. Gaudiano, B. A. Cognitive behavior therapies for psychotic disorders: Current empirical status and future directions. Clinical Psychology: Theory and Practice, 12, 33-50.
9. Gehrs, M., & Goering, P. (1994). The relationship between the working alliance and rehabilitation outcomes of schizophrenia. Psychosocial Rehabilitation Journal, 18, 43-54.
10. Gupta, S., Sonnenburg, S. J., & Frank, B. (1998). Olanzapine augmentation of clozapine. Annals of Clinical Psychiatry, 10, 113-115.
11. Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (1999). Acceptance and Commitment Therapy: An experiential approach to behavior change. New York: Guilford.
12. Henderson, D. C., & Goff, D. C. (1996). Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Journal of Clinical Psychiatry, 57, 395-397.
13. Hogarty, G. E. (2002). Personal therapy for schizophrenia & related disorders: A guide to individualized treatment. New York: Guilford.
14. Hogarty, G. E., Goldberg, S., & Group, C. S. (1973). Drug and sociotherapy in the aftercare of schizophrenic patients: One year relapse rates. Archives of General Psychiatry, 28, 54-64.
15. Hogarty, G. E., Goldberg, S., Schooler, N. R., Ulrich, R. F., & Group, C. S. (1974). Drug and sociotherapy in the aftercare of schizophrenic patients. II: Two year relapse rates. Archives of General Psychiatry, 31, 603-608.
16. Hogarty, G. E., Greenwald, D., Ulrich, R. F., Kornblith, S. J., DiBarry, A. L., Cooley, S., et al. (1997). Three-year trials of personal therapy among schizophrenic patients living with or independent of family II: Effects of adjustment on patients. American Journal of Psychiatry, 154, 1514-1524.
17. Hogarty, G. E., Kornblith, S. J., Greenwald, D., DiBarry, A. L., Cooley, S., Ulrich, R. F., et al. (1997). Three-year trials of personal therapy among schizophrenic patients living with or independent of family I: Description of study and effects on relapse rates. American Journal of Psychiatry, 154, 1504-1513.
18. Hogarty, G. E., Schooler, N. R., Ulrich, R. F., Mussare, F., Herron, E., & Ferro, P. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry, 45, 797-805.
19. Jaspers, K. (1963). General Psychopathology (J. Hoenig & M. Hamilton, Trans.). Manchester, England: Manchester University.
20. Judge, S., Tasman, A., Mellman, L., Yager, J., & Rubin, E. (2004, May). Resolved: The RRC should continue to require that psychiatric residency training programs must demonstrate that the residents have achieved competency in psychodynamic psychotherapy. A Debate. Paper presented at annual meeting of The American Psychiatric Association, New York, NY.
21. Luhrmann, T. M. (2000). Of two minds: The growing disorder in American psychiatry. New York: Knopf.
22. Mellman, T. A., Miller, A. L., Weissman, E. M., Crismon, M. L., Essock, S. M., & Marder, S. R. (2001). Evidence-based pharmacologic treatment for people with severe mental illness: A focus on guidelines and algorithms. Psychiatric Services, 52, 619-625.
23. Morerra, A. L., Barreiro, P., & Cano-Muñoz, J. L. (1999). Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatrica Scandinavica, 99, 305-306.
24. Mowerman, S., & Siris, S. G. (1996). Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Annals of Clinical Psychiatry, 8, 193-197.
25. Mueser, K. T., & Berenbaum, H. (1990). Psychodynamic treatment of schizophrenia: Is there a future? Psychological Medicine, 20, 253-262.
26. Noordsy, D. L., Mellman, T., Larsen, H., Logothetis, L., & O'Keefe, C. D. (2001, June). Outcomes of treatment with multiple antipsychotic agents. Paper presented at the 41st Annual NCDEU Meeting, Scottsdale, AZ.
27. Penn, D. L., Mueser, K. T., Tarrier, N., Gloege, A., & Serrano, D. (2004). Supportive therapy for schizophrenia: A closer look at the evidence. Schizophrenia Bulletin, 30, 101-112.
28. Phillips, S. D., Burns, B. J., Edgar, E. R., Mueser, K. T., Linkins, K. W., Rosenheck, R. A., et al. (2001). Moving Assertive Community Treatment into standard practice. Psychiatric Services, 52 771-779.
29. Potkin, S. G., Thyrum, P. T., Alva, G., Bera, R., Yeh, C., & Arvanitis, L. A. (2002). The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. Journal of Clinical Psychopharmacology, 22, 121-131.
30. Priebe, S., & Gruyters, T. (1993). The role of the helping alliance in psychiatric community care: A prospective study. The Journal of Nervous and Mental Disease, 181, 552-557.
31. Rector, N. A., Seeman, M. V., & Segal, Z. V. (2003). Cognitive therapy for schizophrenia: A preliminary randomized controlled trial. Schizophrenia Research, 63, 1-11.
32. Waddington, J. L., Youssef, H. F., & Kinsella, A. (1998). Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325-329.